• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's After-Market Session

    3/11/24 5:34:44 PM ET
    $ACAD
    $BCEL
    $BNR
    $CGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACAD alert in real time by email

    Gainers

    • CareMax (NASDAQ:CMAX) stock increased by 16.9% to $8.0 during Monday's after-market session. The market value of their outstanding shares is at $29.9 million.
    • Burning Rock Biotech (NASDAQ:BNR) stock moved upwards by 12.34% to $0.91. The market value of their outstanding shares is at $93.4 million.
    • LifeMD (NASDAQ:LFMD) shares increased by 11.19% to $8.84. The market value of their outstanding shares is at $346.5 million. The company's, Q4 earnings came out today.
    • SCWorx (NASDAQ:WORX) stock increased by 9.13% to $2.03. The market value of their outstanding shares is at $2.4 million.
    • Innate Pharma (NASDAQ:IPHA) shares rose 8.79% to $2.66. The market value of their outstanding shares is at $215.0 million.
    • Clearside Biomedical (NASDAQ:CLSD) shares rose 8.41% to $2.19. The company's market cap stands at $163.6 million.

    Losers

    • CytomX Therapeutics (NASDAQ:CTMX) stock declined by 22.3% to $1.95 during Monday's after-market session. The market value of their outstanding shares is at $130.6 million. As per the news, the Q4 earnings report came out today.
    • ACADIA Pharmaceuticals (NASDAQ:ACAD) stock declined by 15.05% to $20.5. The company's market cap stands at $3.3 billion.
    • PaxMedica (NASDAQ:PXMD) stock fell 12.4% to $0.65. The company's market cap stands at $2.9 million.
    • Cognition Therapeutics (NASDAQ:CGTX) stock decreased by 10.16% to $1.77. The company's market cap stands at $56.8 million.
    • Ocular Therapeutix (NASDAQ:OCUL) stock decreased by 9.05% to $8.85. The company's market cap stands at $1.0 billion. The company's, Q4 earnings came out today.
    • Atreca (NASDAQ:BCEL) shares decreased by 8.83% to $0.19. The market value of their outstanding shares is at $7.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACAD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACAD
    $BCEL
    $BNR
    $CGTX

    CompanyDatePrice TargetRatingAnalyst
    ACADIA Pharmaceuticals Inc.
    $ACAD
    3/25/2026$29.00Neutral → Buy
    BofA Securities
    CytomX Therapeutics Inc.
    $CTMX
    3/16/2026$12.00Neutral → Overweight
    Analyst
    LifeMD Inc.
    $LFMD
    3/16/2026$8.00Neutral → Outperform
    Mizuho
    Innate Pharma S.A. ADS
    $IPHA
    3/12/2026$8.00Buy
    BTIG Research
    ACADIA Pharmaceuticals Inc.
    $ACAD
    2/24/2026$33.00Outperform
    Wolfe Research
    ACADIA Pharmaceuticals Inc.
    $ACAD
    2/23/2026$35.00Neutral → Outperform
    Mizuho
    CytomX Therapeutics Inc.
    $CTMX
    1/20/2026$10.00Buy
    Guggenheim
    ACADIA Pharmaceuticals Inc.
    $ACAD
    10/21/2025$33.00Buy
    Citigroup
    More analyst ratings

    $ACAD
    $BCEL
    $BNR
    $CGTX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Ocular Therapeutix Inc.

    SCHEDULE 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

    3/27/26 11:06:43 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by CytomX Therapeutics Inc.

    SCHEDULE 13G/A - CytomX Therapeutics, Inc. (0001501989) (Subject)

    3/26/26 5:40:25 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by ACADIA Pharmaceuticals Inc.

    SCHEDULE 13G/A - ACADIA PHARMACEUTICALS INC (0001070494) (Subject)

    3/26/26 3:06:55 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $BCEL
    $BNR
    $CGTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Thompson Elizabeth H.Z.

    4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)

    3/26/26 8:00:12 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Rhodes Jennifer J

    4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)

    3/26/26 8:00:12 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Owen Adams Catherine

    4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)

    3/26/26 8:00:15 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $BCEL
    $BNR
    $CGTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ACADIA Pharmaceuticals upgraded by BofA Securities with a new price target

    BofA Securities upgraded ACADIA Pharmaceuticals from Neutral to Buy and set a new price target of $29.00

    3/25/26 8:22:46 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CytomX Therapeutics upgraded by Analyst with a new price target

    Analyst upgraded CytomX Therapeutics from Neutral to Overweight and set a new price target of $12.00

    3/16/26 11:34:14 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LifeMD upgraded by Mizuho with a new price target

    Mizuho upgraded LifeMD from Neutral to Outperform and set a new price target of $8.00

    3/16/26 8:33:14 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $ACAD
    $BCEL
    $BNR
    $CGTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-9) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 210793, Application Classification: Efficacy

    9/18/23 10:47:05 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug NUPLAZID (SUPPL-12) with active ingredient PIMAVANSERIN TARTRATE has changed to 'Approval' on 09/15/2023. Application Category: NDA, Application Number: 207318, Application Classification: Efficacy

    9/18/23 10:40:05 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DAYBUE issued to ACADIA PHARMS INC

    Submission status for ACADIA PHARMS INC's drug DAYBUE (ORIG-1) with active ingredient TROFINETIDE has changed to 'Approval' on 03/10/2023. Application Category: NDA, Application Number: 217026, Application Classification: Type 1 - New Molecular Entity

    3/13/23 10:37:07 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $BCEL
    $BNR
    $CGTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

    -Advancing zervimesine clinical development in DLB psychosis – - Meeting with FDA Division of Psychiatry expected by mid-2026 -- Management conference call at 8:30 a.m. ET today - PURCHASE, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), today reported financial results for the fourth quarter and full year ended December 31, 2025. Management will host a live webcast conference call at 8:30 a.m. ET to review these financial results and provide an update on clinical development plans for zervimesine (CT1812) in dementia with Lewy

    3/26/26 7:30:00 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Innate Pharma Reports Full Year 2025 Financial Results and Business Update

    Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) is planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation, including pharma partnering and royalty structures IPH4502 (Nectin-4 ADC) shows preliminary anti-tumor activity with favorable safety profile to date; Phase 1 cohort enrichment ongoing at active dose levels Monalizumab PACIFIC-9 Phase 3 trial, partnered with AstraZeneca, continues to advance toward a planned H2 2026 data readout IPH5201 (anti-CD39 antibody), partnered with AstraZeneca - Interim results of MATISSE Phase 2 trial in non-small cell lung cancer (NSCLC) have been selected for a

    3/26/26 2:00:00 AM ET
    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

    NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ:LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on April 15, 2026, to holders of record at the close of business on April 3, 2026. About LifeMD, Inc.LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's hea

    3/24/26 4:05:00 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $ACAD
    $BCEL
    $BNR
    $CGTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lindstrom Richard L Md bought $461,354 worth of shares (60,229 units at $7.66), increasing direct ownership by 32% to 246,933 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/24/26 6:13:03 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lindstrom Richard L Md bought $69,600 worth of shares (10,000 units at $6.96), increasing direct ownership by 6% to 172,704 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    5/12/25 8:50:46 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Thorp Clay bought $13,800 worth of shares (15,000 units at $0.92), increasing direct ownership by 9% to 176,141 units (SEC Form 4)

    4 - Clearside Biomedical, Inc. (0001539029) (Issuer)

    2/24/25 5:52:59 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACAD
    $BCEL
    $BNR
    $CGTX
    Leadership Updates

    Live Leadership Updates

    View All

    LifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team

    NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the appointment of Atul Kavthekar as Chief Financial Officer, effective today. The Company also announced leadership changes to support its next phase of growth. Marc Benathen, the Company's current CFO, is departing to pursue a new opportunity and will remain with LifeMD through March 31, 2026, to facilitate a smooth transition. "We are thrilled to welcome Atul to LifeMD," said Justin Schreiber, Chairman and CEO of LifeMD. "He is a versatile financial leader who has spent nearly three decades helping healthcare and technology companies scale, and h

    3/16/26 8:00:00 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors

    Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Jonathan M. Poole to its Board of Directors, effective March 3, 2026. Mr. Poole will serve on the Company's Audit Committee and brings deep biopharmaceutical finance leadership experience in supporting global growth and innovation across multiple therapeutic areas and modalities. "Jonathan brings extensive biotechnology corporate leadership experience and a proven track record of supporting significant business growth across complex, global organizations," said Stephen R. Biggar, M.D., Ph.D., Chairman of Acadia's Board of Directors. "His appointment further strengthens the Board's financial and operational expert

    3/3/26 4:05:00 PM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

    SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company's next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology's Board of Directors since 2021 and a seasoned biotech executive, has been appointed interim Chief Executive Officer, effective immediately. Mark Erlander, PhD, Chief Executive Officer, and James Levine, Chief Financial Officer, have stepped down from their res

    1/27/26 7:00:00 AM ET
    $CRDF
    $CTMX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ACAD
    $BCEL
    $BNR
    $CGTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    12/5/24 7:17:43 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    11/26/24 5:02:01 PM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by PaxMedica Inc.

    SC 13G/A - PaxMedica, Inc. (0001811623) (Subject)

    11/14/24 7:22:38 PM ET
    $PXMD
    Medicinal Chemicals and Botanical Products
    Health Care

    $ACAD
    $BCEL
    $BNR
    $CGTX
    Financials

    Live finance-specific insights

    View All

    Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update

    -Advancing zervimesine clinical development in DLB psychosis – - Meeting with FDA Division of Psychiatry expected by mid-2026 -- Management conference call at 8:30 a.m. ET today - PURCHASE, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the "Company" or "Cognition"), today reported financial results for the fourth quarter and full year ended December 31, 2025. Management will host a live webcast conference call at 8:30 a.m. ET to review these financial results and provide an update on clinical development plans for zervimesine (CT1812) in dementia with Lewy

    3/26/26 7:30:00 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Innate Pharma Reports Full Year 2025 Financial Results and Business Update

    Lacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) is planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation, including pharma partnering and royalty structures IPH4502 (Nectin-4 ADC) shows preliminary anti-tumor activity with favorable safety profile to date; Phase 1 cohort enrichment ongoing at active dose levels Monalizumab PACIFIC-9 Phase 3 trial, partnered with AstraZeneca, continues to advance toward a planned H2 2026 data readout IPH5201 (anti-CD39 antibody), partnered with AstraZeneca - Interim results of MATISSE Phase 2 trial in non-small cell lung cancer (NSCLC) have been selected for a

    3/26/26 2:00:00 AM ET
    $IPHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

    NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ:LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on April 15, 2026, to holders of record at the close of business on April 3, 2026. About LifeMD, Inc.LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's hea

    3/24/26 4:05:00 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care